Quick Answer
Moleculin Biotech, Inc. reported Stockholders Equity of $15.01 million for the year ending 2025.
- Moleculin Biotech, Inc. showed an increase of +33.9% in Stockholders Equity from 2024 to 2025.
- This data is from Moleculin Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: -$688.3 thousand | Q2 2016: $17.23 million | Q3 2016: $16.24 million | Q1 2017: $16.14 million | Q2 2017: $19.27 million | Q3 2017: $18.65 million | Q1 2018: $20.57 million | Q2 2018: $16.75 million | Q3 2018: $14.97 million | Q1 2019: $14.68 million | Q2 2019: $22.09 million | Q3 2019: $18.98 million | Q1 2020: $15.29 million | Q2 2020: $15.63 million | Q3 2020: $14.47 million | Q1 2021: $88.52 million | Q2 2021: $84.70 million | Q3 2021: $81.26 million | Q1 2022: $72.67 million | Q2 2022: $66.36 million | Q3 2022: $58.42 million | Q1 2023: $45.68 million | Q2 2023: $40.27 million | Q3 2023: $35.14 million | Q1 2024: $24.99 million | Q2 2024: $19.41 million | Q3 2024: $17.41 million | Q1 2025: $13.79 million | Q2 2025: -$3.59 million | Q3 2025: -$26.92 million.
- Over the full 11 years of available data (2015 to 2025), Moleculin Biotech, Inc.'s Stockholders Equity has grown by 2,114.2%.
- Historical annual values: Fiscal year 2025: $15.01 million | Fiscal year 2024: $11.21 million | Fiscal year 2023: $30.93 million | Fiscal year 2022: $52.19 million | Fiscal year 2021: $78.99 million | Fiscal year 2020: $17.76 million | Fiscal year 2019: $15.57 million | Fiscal year 2018: $14.27 million | Fiscal year 2017: $17.12 million | Fiscal year 2016: $14.96 million | Fiscal year 2015: -$745.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: